今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

LG Display抢先三星获iPhone 16 Pro Max OLED量产许可，显示面板大战再升级

北京讯 近日，据外媒报道，韩国显示器巨头LG Display已获得苹果公司iPhone 16 Pro Max OLED显示面板的量产许可，领先于其主要竞争对手三星Display。这一消息引发了业界的广泛关注。

LG Display率先获得iPhone 16 Pro Max OLED量产许可

据悉，LG Display和三星Display此前一直是苹果公司iPhone OLED显示面板的主要供应商。然而，在iPhone 16 Pro Max的OLED显示面板订单上，LG Display却抢先一步获得了许可。

有分析人士认为，LG Display能够领先三星，主要得益于其在OLED面板技术方面的突破。LG Display近年来在OLED面板的良率和成本控制方面取得了显著进步，这也使其在与三星Display的竞争中占据了优势。

三星Display表示将继续努力

对于LG Display获得iPhone 16 Pro Max OLED量产许可的消息，三星Display方面表示，他们将继续努力，为苹果公司提供最优质的OLED显示面板。

三星Display是全球最大的OLED显示面板供应商，在iPhone OLED显示面板市场占据主导地位。然而，近年来，LG Display在OLED面板技术方面不断进步，对三星Display形成了巨大的挑战。

显示面板大战再升级

LG Display获得iPhone 16 Pro Max OLED量产许可，标志着其在与三星Display的竞争中取得了重要胜利。这也将进一步加剧智能手机显示面板市场竞争的激烈程度。

以下是一些可以参考的新闻来源：

• 曝LG获iPhone 16 Pro Max OLED量产许可 领先三星 https://www.eet-china.com/mp/a322081.html
• 传三星显示、LG Display均获准量产苹果iPhone 16 Pro OLED面板 https://www.eet-china.com/mp/a320762.html
• 曝LG 获iPhone 16 Pro Max OLED 量产许可领先三星 https://www.youm7.com/story/2024/5/22/%D8%AA%D8%B3%D8%B1%D9%8A%D8%A8%D8%A7%D8%AA-%D8%AC%D8%AF%D9%8A%D8%AF%D8%A9-%D9%84%D9%80-%D8%A2%D9%8A%D9%81%D9%88%D9%86-16-%D8%A8%D8%B1%D9%88-%D9%85%D8%A7%D9%83%D8%B3-%D9%85%D8%A7-%D8%A7%D9%84%D8%B0%D9%89-%D9%8A%D9%85%D9%83%D9%86/6584944